Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | AHCY | P23526 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27430559 | 0.92 | ADORA3 (0.49) | SLC29A1ADORA3ADORA1 | |
| SCHEMBL27428742 | 0.89 | SLC29A1 (0.56) | SLC29A1ADORA3AHCYADORA1 | |
| SCHEMBL27425126 | 0.89 | SLC29A1 (0.59) | SLC29A1ADORA3AHCYADORA1PRKAG1 | |
| SCHEMBL27427947 | 0.89 | SLC29A1 (0.61) | SLC29A1ADORA3ADORA1PRKAG1PRKAA1 | |
| SCHEMBL27426560 | 0.88 | SLC29A1 (0.62) | SLC29A1ADORA3AHCYADORA1 | |
| SCHEMBL27424987 | 0.87 | SLC29A1 (0.57) | SLC29A1ADORA3AHCYADORA1 | |
| SCHEMBL27428243 | 0.87 | SLC29A1 (0.57) | SLC29A1ADORA3AHCYADORA1 | |
| SCHEMBL27423745 | 0.86 | ADORA3 (0.54) | SLC29A1ADORA3 | |
| SCHEMBL27425390 | 0.85 | SLC29A1 (0.62) | SLC29A1ADORA3ADORA1 | |
| SCHEMBL27426665 | 0.85 | SLC29A1 (0.59) | SLC29A1ADORA3AHCYADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |